Table 2.
Distribution of prothrombotic risk factors in individuals without and with thrombosis.
| Risk factor, n (%) | Without Thrombosis aCL Category* | With Thrombosis aCL Category* | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Normal n = 16 |
Low n = 17 |
Intermediate n = 16 |
High n = 18 |
Total n = 67 |
Normal n = 4 |
Low n = 5 |
Intermediate n = 4 |
High n = 7 |
Total n = 20 |
|
| aCL-IgG | 2 (13) | 7 (41) | 7 (44) | 14 (78) | 30 (45) | 0 | 2 (40) | 4 (100) | 6 (86) | 12 (60) |
| aCL-IgM | 1 (6) | 4 (24) | 2 (13) | 5 (28) | 12 (18) | 0 | 1 (20) | 0 | 2 (29) | 3 (15) |
| LAC | 1 (6) | 2 (12) | 3 (19) | 5 (28) | 11 (16) | 0 | 1 (20) | 1 (25) | 7 (100) | 9 (45) |
| aβ2GPI | 2 (13) | 2 (12) | 5 (31) | 6 (33) | 15 (22) | 2 (50) | 0 | 0 | 5 (71) | 7 (35) |
| Protein C deficiency | 0 | 2 (12) | 4 (25) | 0 | 6 (9) | 1 (25) | 0 | 0 | 1 (14) | 2 (10) |
| Protein S deficiency | 0 | 0 | 1 (6) | 1 (6) | 2 (3) | 0 | 0 | 0 | 0 | 0 |
| APCR** | 2 (13) | 0 | 2 (13) | 1 (6) | 7 (7) | 0 | 0 | 0 | 1 (14) | 1 (5) |
| Factor V506 | 1 (6) | 0 | 2 (13) | 0 | 3 (4) | 1 (25) | 0 | 0 | 0 | 1 (5) |
| Acquired | 1 (6) | 0 | 0 | 1 (6) | 2 (3) | 0 | 0 | 0 | 1 (14) | 1 (5) |
| MTHFR | ||||||||||
| Heterozygous | 9 (56) | 7 (41) | 7 (44) | 8 (44) | 31 (46) | 3 (75) | 1 (20) | 3 (75) | 5 (71) | 12 (60) |
| Homozygous | 3 (19) | 6 (35) | 2 (13) | 3 (17) | 14 (21) | 0 | 1 (20) | 1 (25) | 0 | 2 (10) |
| Prothrombin gene mutation*** | n/a | 0 | 1 (6) | 0 | 1 (1) | n/a | 0 | 1 (25) | 0 | 1 (5) |
*
aCL categories were defined using aCL-IgG test results at entry: normal < 23 GPL; low 23.0–29.9 GPL; intermediate 30–49.9 GPL; high ≥ 50 GPL.
**
One individual was heterozygotic for factor V Leiden and had a normal APCR. This individual was taking coumadin.
***
Prothrombin gene mutation was not evaluated in the aCL normal group.